Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade
Our study revealed that KRAS, ANO1, COL14A1, LTBP1. ERBB4 and PCSK5 mutation could serve as predictive biomarkers for patients with Anti-PD-(L)1+Anti-CTLA-4 combination therapy. Our systematic nomogram demonstrates significant potential in predicting the prognosis for NSCLC patients with responsive to dual PD-1/CTLA-4 blockade.
Authors
- Chunxia Su (ORCID: https://orcid.org/0000-0003-1632-9487)
- Li Wang (ORCID: https://orcid.org/0000-0001-5691-9946)
- Xin Yu (ORCID: https://orcid.org/0009-0001-8768-4112)
- Jing Zhao (ORCID: https://orcid.org/0000-0002-1557-9022)
- Li Liu
Institutions
- Shanghai Pulmonary Hospital (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/itt.s476040
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Natural Science Foundation of China
- Shanghai Pulmonary Hospital